IP Library Granted Patent US 10,752,668
Granted Patent B2
US 10,752,668 · App. 15/327,517 · Granted Aug 25, 2020

Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Inventors: Sophie Agaugue (Paris, FR); Lorenzo Tibaldi (Paris, FR); Klervi Even-Desrumaux (Antony, FR); Dmitry Trubetskoy (Arcueil, FR); Franck Perez (Paris, FR); Sebastian Amigorena (Paris, FR); Cécile Bauche (Paris, FR)
Assignees: Theravectys; Institut Curie; Centre National de la Recherche Scientifique; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (INSERM)
C07K14/70503A61K35/17C07K16/00C12N5/0636C12N5/0646A61K38/00C07K2317/622C07K2319/00C07K2319/03C07K2319/22C12N2510/00C12N2799/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,668
App. No.
15/327,517
Granted
Aug 25, 2020
Kind
B2
Abstract

The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.

Claims (30)

1. A chimeric antigen receptor comprising:

a binding domain;

a transmembrane domain;

a hook-binding domain comprising a streptavidin-binding peptide; and

an activation domain comprising a T cell activating fragment comprising an amino acid sequence having at least 90% amino acid sequence identity to the amino acid sequence selected from the group consisting of:

the amino acid fragment of sequence PKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD VLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG HDGLY from SEQ ID NO:3;

SEQ ID NO:4;

the amino acid fragment of sequence KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL from SEQ ID NO:5;

SEQ ID NO:6;

SEQ ID NO:7,

SEQ ID NO:8,

SEQ ID NO:33, and

SEQ ID NO:34,

the hook-binding domain being encoded by the nucleic acid sequence SEQ ID NO:2;

the hook-binding domain being located in the intracytoplasmic region, between the transmembrane domain and the activation domain, between two activation domains or at the intracytoplasmic C-terminus of the chimeric antigen receptor;

the binding domain being located in the extracytoplasmic region of the chimeric antigen receptor; and

the T cell activating fragment being located in the intracytoplasmic region of the chimeric antigen receptor.

2. The chimeric antigen receptor of claim 1 , wherein the binding domain comprises a single-chain Fv antibody or a nanobody.

3. The chimeric antigen receptor of claim 1 , wherein the chimeric antigen receptor comprises the amino acid sequence of any of SEQ ID NO:46, SEQ ID NO:48, or SEQ ID NO:50.

4. The chimeric antigen receptor of claim 1 , wherein the activation domain comprises a T cell activating fragment comprising the amino acid sequence selected from the group consisting of:

the amino acid fragment of sequence PKLCYLLDGILFIYGVILTALFLRVKFSRSADAPAYQQGQNQLYNELNLGRREEY DVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG KGHDGLY from SEQ ID NO:3;

SEQ ID NO:4;

the amino acid fragment of sequence KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL from SEQ ID NO:5;

SEQ ID NO:6,

SEQ ID NO:7,

SEQ ID NO:8,

SEQ ID NO:33, and

SEQ ID NO:34.

5. The chimeric antigen receptor of claim 1 , wherein the activation domain comprises the amino acid fragment of sequence KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL from the amino acid sequence SEQ ID NO:5 and

the amino acid fragment of sequence PKLCYLLD GILFIYGVILTALFLRVKFSRSADAPAYQQGQNQLYNELNLGRREEY DVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG KGHDGLY from the amino acid sequence SEQ ID NO:3.

Assignments (2)
MERGER Recorded Apr 16, 2020
From: UNIVERSITE PIERRE ET MARIE CURIE; UNIVERSITE PARIS-SORBONNE (PARIS IV)
To: SORBONNE UNIVERSITÉ
Reel/Frame 052412/0952 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2018
From: AGAUGUE, SOPHIE; TIBALDI, LORENZO; EVEN-DESRUMAUX, KIERVI; TRUBETSKOY, DMITRY; PEREZ, FRANCK; AMIGORENA, SEBASTIAN; BAUCHE, CECILE
To: THERAVECTYS; INSTITUT CURIE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; UNIVERSITE PIERRE ET MARIE CURIE; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 045261/0220 →
Priority Claims (1)
EP 15306036 · Jun 29, 2015 · regional
Continuity (3)
Provisional Application 62155811 · May 1, 2015
Provisional Application 62028889 · Jul 25, 2014
Related Publication 20170166623A1 · Jun 15, 2017
Cited By (2)
US 12,516,099 US 12,522,660